Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
01 Maio 2023 - 9:30AM
Business Wire
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company
developing MultiStem® (invimestrocel) cell therapy for critical
care indications, announced today their participation in the
Cellular Therapeutics in Trauma and Critical Care’s (CTTACC)
conference, “Cellular Therapies and Transfusion Medicine in Trauma
and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.
Presented by the University of California San Francisco and
Colorado State University, this conference is the fifth in a series
of conferences supporting the development and translation of novel
therapies in trauma and critical care medicine, a field with
limited therapeutic options. This conference will bring together
the expertise and input of cell therapy companies, clinicians,
basic scientists, industry, FDA, NIH, AABB, DARPA, BARDA and DOD
representatives to discuss current research and existing barriers
in the translation of these novel therapies in trauma and critical
care medicine. Previous conferences have resulted in multiple
cross-disciplinary collaborations and grants for pre-clinical
studies and clinical trials.
Dr. Willie Mays, Executive Vice President and Head of
Regenerative Medicine and Neuroscience Programs, has been invited
to participate in this conference. On Tuesday, May 9th, he will be
moderating a session titled, “Cellular and Novel Therapeutics in
Neurotrauma and Polytrauma,” which will focus on novel blood and
cell therapies for traumatic brain injury (TBI) and spinal cord
injury (SCI).
“Athersys’ primary focus at this time is the clinical
development of our proprietary cell therapy product, MultiStem, and
its ability to treat and enhance recovery in patients suffering
from acute severe injuries such as stroke and trauma,” commented
Dr. Mays. “Opportunities to collaborate with other industry experts
and advance the scientific understanding of novel therapies, like
our MultiStem therapy, is critical for the clinical translation of
cellular therapies now and in the future. I look forward to
participating in this conference as its mission directly aligns
with that of Athersys, to help patients in the acute care setting
where there is an unmet medical need due to the limitations in
standard of care.”
The following are specific details regarding Dr. Mays’
participation in the Cellular Therapies and Transfusion Medicine in
Trauma and Critical Care conference:
Event:
Session 3 | Cellular and Novel
Therapeutics in Neurotrauma and Polytrauma
Date:
Tuesday, May 9th, 2023
Time:
1:15 p.m. ET
Location:
Omni Scottsdale Resort & Spa,
Scottsdale, Arizona
Please visit https://cttacc.org/ for additional information and
registration.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005015/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Athersys (NASDAQ:ATHX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Athersys (NASDAQ:ATHX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024